Navigation Links
NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
Date:11/1/2007

MILWAUKEE, Nov. 1 /PRNewswire-FirstCall/ -- Merge Technologies Incorporated, d.b.a. Merge Healthcare (Nasdaq: MRGE; TSX: MRG), today announced that the Company received a written notification from the NASDAQ Listing Qualifications Panel stating that the panel determined to continue the listing of the Company's common stock on The NASDAQ Stock Market subject to the Company's filing of its Form 10-Q for the quarter ended June 30, 2007 by no later than January 29, 2008. As indicated in the Company's news release dated October 29, 2007, the Company currently expects to file, on or before December 31, 2007: (i) its restated audited financial statements for the years ended December 31, 2004, 2005 and 2006, as well as other restated financial information previously included in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, (ii) its restated unaudited financial statements included in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, and (iii) its unaudited Quarterly Reports on Form 10-Q for the quarters ended June 30, 2007 and September 30, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/MRGELOGO)

Merge Healthcare is a market leader in the development and delivery of medical imaging and information management software and services. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at http://www.mergehealthcare.com.

All trademarks appearing in this release are the property of Cedara Software Corp. and/or Merge Healthcare.

Cautionary Notice Regarding Forward-Looking Statements

This announcement may include forward-looking statements within the meaning and subject to the protections of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this announcement, the words "will," "believes," "intends," "anticipates," "expects" and similar expressions of the future are intended to assist you in identifying such forward-looking statements. Such forward-looking statements include, among others, statements regarding the timing of our completion of our restatements and filings of related SEC reports.

Any number of factors could cause the actual timing or results to differ from the results contemplated by such forward-looking statements, including, but not limited to: the restatement may take longer to complete than expected; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; risks and effects of the past and current restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; costs, risks and effects of legal proceedings and investigations, including the formal investigation being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; the uncertainty created by and the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company's senior management; and other risk factors detailed in the Company's filings with the Securities and Exchange Commission.

You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. We do not have, or undertake any obligation to, publicly update, revise or correct any of the forward-looking statements after the date of this announcement, or after the respective dates on which such statements otherwise are made, whether as a result of new information, future events or otherwise. This announcement should be read in conjunction with the risk factors, financial information and other information contained in the filings that the Company makes and previously has made with the Securities and Exchange Commission.


'/>"/>
SOURCE Merge Technologies Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NASDAQ will continue to list Merge
2. NASDAQ grants Merge more time for compliance
3. NASDAQ will continue to list Merge
4. No word on NASDAQ extension for Merge
5. NASDAQ puts Merge on notice again
6. Flat panel displays
7. Panel stresses drawing outside biotech firms to state
8. National stem-cell panel, including UW profs, urges close watch on research
9. Star panel re-evaluates Sarbanes-Oxley one year in at SEC headquarters
10. Distance Education Conference Selects Sonic Foundry to Make Keynotes, Panel Presentations Available On-Demand
11. State to offer $850K in high-tech training grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In a recent ... team of scientists in Guangzhou, China ... of NR2F6 in patients with early cervical cancer correlates with ... cancer tissue as well as in the normal tissue surrounding ... study and the first that I am aware of that ...
(Date:12/7/2016)... ... ... Dwyer Dodge grew up hearing stories of the sea monster her father pulled from the ... turtle entangled in the lines of one of his lobster pots. He freed it and ... could remember ever seeing one so large so close to shore. After a couple of ...
(Date:12/6/2016)... ... ... Discovering new clues to natural treatments that could allow our bodies to ... And searching for keys to our immune systems by studying parasite-resistant fish. These are ... Edith and Peter O’Donnell Awards by The Academy of Medicine, Engineering and ...
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 ... of Santosh Kesari , MD, PhD, FANA, FAAN ... his experience in neurology and clinical trials to assist ... for treatment of stroke. The AmnioStem product is a universal ... previously shown therapeutic activity in animal models of stroke ...
Breaking Biology Technology:
(Date:12/7/2016)... Avanade is helping Williams Martini Racing, one of ... biometric data in order to critically analyse every aspect ... against their rivals after their impressive, record-breaking pit stop ... with Williams during the 2016 season to capture and ... rate, temperature and peak acceleration) for key members of ...
(Date:12/6/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, and the Prison ... (5) year funding commitment by Securus to PEP ... and reentry support to more inmates and their ... the Prison Entrepreneurship Program (PEP) is an independent ...
(Date:11/30/2016)... Nov. 30, 2016 Not many of us realize that we spend ? ... so we need to do it well. Inadequate sleep levels have been found to ... stroke, diabetes, and even cancer. Maybe now is the best time to ... help them to manage their sleep quality? Continue Reading ... ...
Breaking Biology News(10 mins):